Research Papers: Immunology:
Quantitative proteomics reveals Piccolo as a candidate serological correlate of recovery from Guillain-Barré syndrome
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2015 views | HTML 2080 views | ?
Lourdes Mateos-Hernández1,*, Margarita Villar1,*, Ernesto Doncel-Pérez2, Marco Trevisan-Herraz3, Ángel García-Forcada2, Francisco Romero Ganuza2, Jesús Vázquez3 and José de la Fuente1,4
1 SaBio. Instituto de Investigación en Recursos Cinegéticos IREC-CSIC-UCLM-JCCM, Ronda de Toledo s/n, 13005 Ciudad Real, Spain
2 Hospital Nacional de Parapléjicos, Servicio de Salud de Castilla La Mancha (SESCAM), Finca La Peraleda s/n, 45071 Toledo, Spain
3 Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain
4 Department of Veterinary Pathobiology, Center for Veterinary Health Sciences, Oklahoma State University, Stillwater, OK, USA
* These authors have contributed equally to this manuscript
José de la Fuente, email:
Keywords: immunity, neuropathy, proteomics, biomarker, Guillain-Barré, neurology, Immunology and Microbiology Section, Immune response, Immunity
Received: August 24, 2016 Accepted: October 13, 2016 Published: October 20, 2016
Guillain-Barré syndrome (GBS) is an autoimmune-mediated peripheral neuropathy of unknown cause. However, about a quarter of GBS patients have suffered a recent bacterial or viral infection, and axonal forms of the disease are especially common in these patients. Proteomics is a good methodological approach for the discovery of disease biomarkers. Until recently, most proteomics studies of GBS and other neurodegenerative diseases have focused on the analysis of the cerebrospinal fluid (CSF). However, serum represents an attractive alternative to CSF because it is easier to sample and has potential for biomarker discovery. The goal of this research was the identification of serum biomarkers associated with recovery from GBS. To address this objective, a quantitative proteomics approach was used to characterize differences in the serum proteome between a GBS patient and her healthy identical twin in order to lessen variations due to differences in genetic background, and with additional serum samples collected from unrelated GBS (N = 3) and Spinal Cord Injury (SCI) (N = 3) patients with similar medications. Proteomics results were then validated by ELISA using sera from additional GBS patients (N = 5) and healthy individuals (N = 3). All GBS and SCI patients were recovering from the acute phase of the disease. The results showed that Piccolo, a protein that is essential in the maintenance of active zone structure, constitutes a potential serological correlate of recovery from GBS. These results provided the first evidence for the Piccolo´s putative role in GBS, suggesting a candidate target for developing a serological marker of disease recovery.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.